Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 04, 2024	Apr. 30, 2018	Dec. 31, 2023	Jun. 30, 2024	Jul. 31, 2024
Collaboration Agreement [Member]
Loss Contingencies [Line Items]
Aggregate payment of production facility	$ 135.0
Collaboration Agreement [Member] | BiBo Biopharma Engineering Co., Ltd.
Loss Contingencies [Line Items]
Additional percentage of milestones payment payable upon achievement	$ 61.5
Upfront payment				$ 60.0
Collaboration Agreement [Member] | BiBo Biopharma Engineering Co., Ltd. | Subsequent Events
Loss Contingencies [Line Items]
Upfront payment					$ 60.0
BiBo Collaboration Agreement [Member]
Loss Contingencies [Line Items]
Agreement date	Apr. 04, 2024
Teva Agreement [Member]
Loss Contingencies [Line Items]
Nonrefundable upfront payment		$ 6.0
Payment upon achievement of certain clinical and commercial milestones		65.0
Asset transfer and license agreement, termination period after written notice				120 days
Asset transfer and license agreement, termination period notice of breach				60 days
Asset transfer and license agreement termination notice period if bankruptcy petition filed				60 days
Milestone payments			$ 2.5
Teva Agreement [Member] | Teva's Development Program
Loss Contingencies [Line Items]
Payment upon achievement of certain clinical and commercial milestones		$ 2.5